Financial Performance - The company's operating revenue for Q3 2025 reached ¥406,794,256.65, representing a 2.76% increase year-over-year[4] - Net profit attributable to shareholders was ¥69,861,041.47, up 13.29% compared to the same period last year[4] - The basic earnings per share increased by 15.08% to ¥0.1366 for the current period[4] - Total operating revenue for the current period reached ¥1,167,602,224.43, an increase of 7.4% compared to ¥1,082,325,012.30 in the previous period[21] - Net profit for the current period was ¥204,312,790.12, representing a growth of 11.4% from ¥183,343,938.37 in the previous period[22] - Basic earnings per share increased to ¥0.3573 from ¥0.3232, marking a rise of 10.6%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,310,054,116.09, reflecting a 3.93% increase from the end of the previous year[4] - Total assets reached ¥2,310,054,116.09, compared to ¥2,222,709,961.44, indicating a growth of 3.9%[19] - Total liabilities increased to ¥834,279,303.35 from ¥814,055,748.31, reflecting a rise of 2.7%[19] - Non-current assets totaled ¥1,480,068,112.76, up from ¥1,398,754,616.01, showing an increase of 5.8%[19] - Current liabilities decreased slightly to ¥558,402,423.00 from ¥577,595,822.70, a decline of 3.4%[19] Cash Flow - Operating cash inflow for the current period reached ¥1,354,172,234.70, an increase of 11.6% compared to ¥1,212,962,998.57 in the previous period[24] - Net cash flow from operating activities was ¥325,422,401.90, slightly up from ¥323,591,496.43 in the previous period[24] - Cash inflow from investment activities totaled ¥488,203,748.46, significantly higher than ¥154,621,615.16 in the previous period[25] - Net cash flow from investment activities was -¥272,215,709.56, worsening from -¥224,909,519.62 in the previous period[25] - Cash inflow from financing activities was ¥81,840,000.00, down from ¥168,434,775.00 in the previous period[25] - Net cash flow from financing activities was -¥199,338,269.68, compared to -¥186,197,100.44 in the previous period[25] - The ending balance of cash and cash equivalents was ¥135,355,790.28, up from ¥111,439,210.26 in the previous period[25] Investments - The company reported a significant increase in investment income of 1339.59%, totaling ¥3,513,977.61, primarily due to increased financial management returns[8] - The company reported an investment income of ¥3,513,977.61, recovering from a loss of ¥283,479.34 in the previous period[22] - The company received ¥479,831,813.95 from investment recoveries, a substantial increase from ¥152,241,110.00 in the previous period[25] - The company paid ¥570,471,075.00 for investments, significantly higher than ¥223,000,000.00 in the previous period[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,101[11] - The largest shareholder, Peng Yixing, holds 32,231,511 shares, representing a significant portion of the company's equity[12] - The company has a total of 165,183,790 shares subject to lock-up agreements, with 2,831,750 shares released during the period[15] - The company has a total of 96,694,533 shares under lock-up for Peng Yixing, which will remain locked for 75% of the term[14] - The company has not reported any changes in the status of its major shareholders participating in margin trading activities[12] Other Financial Metrics - The company’s weighted average return on equity was 5.15%, an increase of 0.41% from the previous year[4] - The company received government subsidies amounting to ¥20,147,396.69, a 73.66% increase compared to the previous year[8] - Research and development expenses for the current period were ¥50,894,409.75, compared to ¥44,733,074.43, an increase of 13.4%[21] - Cash and cash equivalents decreased by 48.67% to ¥148,770,600.97, mainly due to increased purchases of financial products[9] - The company reported a decrease in cash and cash equivalents, with a balance of ¥148,770,600.97 compared to ¥289,846,781.19 at the beginning of the period, reflecting a decline of approximately 48.7%[17] - Trading financial assets increased significantly to ¥321,713,269.90 from ¥178,481,242.87, marking an increase of about 80.0%[17] - Inventory levels rose to ¥215,956,705.08 from ¥195,673,582.44, indicating an increase of approximately 10.4%[17] - Accounts receivable slightly decreased to ¥81,576,277.11 from ¥83,256,881.36, a decline of about 2.0%[17] - The company’s total current assets include various components, with a notable increase in prepayments to ¥15,806,640.89 from ¥13,223,949.61, an increase of about 19.5%[17] - The company’s total receivables financing increased to ¥7,373,398.77 from ¥2,770,415.37, reflecting a growth of approximately 165.5%[17]

国金证券股份有限公司 关于 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 保荐人（主承销商） （成都市青羊区东城根上街 95 号） 二〇二五年十月 江西三鑫医疗科技股份有限公司向不特定对象发行可转换公司债券之发行保荐书 声 明 本保荐人及保荐代表人根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司证券发行注册管理办法》《证券发行上市保荐业务管理办法》 等有关法律、行政法规和中国证券监督管理委员会的规定，诚实守信，勤勉尽责， 严格按照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书，并 保证所出具文件的真实性、准确性和完整性。 3-1-1 | 声 | 明 1 | | --- | --- | | 目 | 录 2 | | 释 | 义 3 | | 第一节 | 本次发行基本情况 4 | | | 一、保荐人项目人员情况 4 | | | 二、发行人基本情况 4 | | | 三、保荐人及其关联方与发行人及其关联方之间的利害关系及主要业务往来 | | | 情况 5 | | | 四、保荐人内部审核程序和内核意见 6 | | | 五、关于有偿聘请第三方机构和个人等相关行为的核 ...

国金证券股份有限公司 关于 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券 之 二〇二五年十月 上市保荐书 江西三鑫医疗科技股份有限公司向不特定对象发行可转换公司债券之上市保荐书 保荐人（主承销商） 声 明 （成都市青羊区东城根上街 95 号） 3-3-1 | 声 | 明 1 | | --- | --- | | 目 | 录 2 | | 第一节 | 发行人概况 3 | | | 一、发行人基本情况 3 | | | 二、主营业务 4 | | | 三、主要经营和财务数据及指标 4 | | | 四、发行人存在的主要风险 5 | | 第二节 | 本次发行情况 13 | | | 一、本次发行履行的内部程序 13 | | | 二、本次发行的基本情况 13 | | | 三、本次可转债发行的基本条款 16 | | | 四、违约责任及争议解决机制 26 | | 第三节 | 本次发行的保荐代表人、协办人及项目组其他成员 28 | | | 一、本保荐机构指定保荐代表人情况 28 | | | 二、本次证券发行项目协办人及其项目组成员 28 | | | 三、保荐机构和相关保荐代表人的联系地址、电话和其他通讯方式 28 | | ...

江西三鑫医疗科技股份有限公司 审计报告 大信审字[2023]第 6-00005 号 大信会计师事务所(特殊普通合伙) 审计报告 大信审字[2023]第 6-00005 号 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 6-1-1 WUYIGE Certified Public Accountants U.P. 1 号 15/F.Xuevuan International Tower No.1Zhichun Road,Haidian Dist Beljing,China,100083 江西三鑫医疗科技股份有限公司全体股东: 一、审计意见 我们审计了江西三鑫医疗科技股份有限公司(以下简称"贵公司")的财务报表,包括 2022年12月31日的合并及母公司资产负债表,2022年度的合并及母公司利润表、合并及母 公司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 贵公司 2022年 ...

公司本次向不特定对象发行可转换公司债券事项尚需通过深圳证券交易所 审核，并获得中国证券监督管理委员会同意注册的决定后方可实施，该事项能否 通过审核、注册以及最终通过审核、注册的时间仍存在不确定性。公司将根据该 事项的审核进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告 江西三鑫医疗科技股份有限公司董事会 2025 年 10 月 29 日 关于向不特定对象发行可转换公司债券申请 获得深圳证券交易所受理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日收到深圳证券交易所出具的《关于受理江西三鑫医疗科技股份有限公司向不特 定对象发行可转换公司债券申请文件的通知》（深证上审[2025]209 号），深圳 证券交易所对公司报送的向不特定对象发行可转换公司债券申请文件进行了核 对，认为申请文件齐备，决定予以受理。 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-064 江西三鑫医疗科技股份有限公司 ...

股票简称：三鑫医疗 股票代码：300453 保荐人（主承销商） （成都市青羊区东城根上街 95 号） 二〇二五年十月 江西三鑫医疗科技股份有限公司 Jiangxi Sanxin Medtec Co., Ltd. （江西省南昌县小蓝经济开发区富山大道 999 号） 向不特定对象发行可转换公司债券 募集说明书 （申报稿） 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券募集说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-1 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券募集说明书 重大事项提示 公司特别提请投资者注意，在作出投资决策之前，务必仔细阅读本募集说明 书正文内 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-063 江西三鑫医疗科技股份有限公司 关于控股子公司变更医疗器械生产许可证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）控股子公司成都威力生 生物科技有限公司（以下简称"成都威力生"）因生产经营需要，对《医疗器械生 产许可证》的生产地址进行变更并完成了变更登记手续，于近日取得了四川省药品 监督管理局换发的《医疗器械生产许可证》，现将具体内容公告如下： | 变更事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 生产地址 | 高新区科园南路 88 号 10 栋 3 楼 303、304 号；高新区科园南路 88 号 10 栋 3 楼 302 号仓库 5、仓库 6、仓库 7；高新区科韵路 | 高新区科园南路 88 号 10 栋 3 楼 303、304 号；高新区科园南路 88 号 10 栋 3 楼 302 号仓库 5、仓库 6、仓库 7；高新区科韵 路 368 号 1 栋 1 单元 3 楼 301 号；眉山 | | | ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-062 江西三鑫医疗科技股份有限公司 关于2024年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、江西三鑫医疗科技股份有限公司（以下简称"公司"）本次回购注销的 股份数量为 313,250 股，占回购前公司总股本 522,397,525 股的 0.06%，本次限 制性股票回购注销涉及的人数为 31 人，回购价格为 3.1 元/股加上银行同期存款 利息之和，回购资金总额为 985,277.05 元（其中限制性股票回购款为 971,075 元，银行同期存款利息为 14,202.05 元）。 2、截至本公告披露之日，上述限制性股票已在中国证券登记结算有限责任 公司深圳分公司完成注销手续。 3、本次回购注销完成后，公司总股本由 522,397,525 股减少为 522,084,275 股。 6、2024 年 9 月 2 日，公司披露了《关于 2024 年限制性股票激励计划授予 登记完成的公告》（公告编号：2024-079），公司完成了本次激 ...

Core Viewpoint - The development of non-toxic medical plastics is crucial due to the health risks associated with DEHP, a common plasticizer in PVC medical devices, which poses reproductive health hazards [1][2][3] Group 1: Health Risks of DEHP - DEHP is widely used in PVC medical devices due to its excellent properties but has significant reproductive toxicity and carcinogenicity [2] - Long-term exposure to DEHP can lead to severe reproductive health issues, including male reproductive system damage and increased miscarriage rates in women [2] - The need for alternatives to DEHP is urgent, as existing substitutes lack reliable safety data and are not developed with domestic intellectual property [2] Group 2: Collaborative Research Efforts - The Beijing Chemical Industry Research Institute is leading a collaborative effort with five other organizations to develop non-phthalate plasticizers [3] - The collaboration encompasses the entire chain from molecular design to production and safety testing, integrating various expertise [3] - Key partners include the Chinese Academy of Sciences and Fudan University, which contribute to the design and safety evaluation of new plasticizers [3] Group 3: Challenges Ahead - The project faces three main challenges: designing a non-toxic molecular structure while avoiding patent barriers, conducting reproductive toxicity assessments, and ensuring compliance with medical standards for production [4] - A production line capable of annual output of 100 tons is planned, with a timeline set for completion of key tasks by June 2028 [4][5] - Successful implementation will lead to the introduction of safer medical devices, such as blood transfusion bags and dialysis tubes, into hospitals [5]